Authors
Manoj M Lalu, David Moher, John Marshall, Dean Fergusson, Shirley HJ Mei, Malcolm Macleod, Gilly Griffin, Alexis F Turgeon, Michael Rudnicki, Jason Fishman, Marc T Avey, Becky Skidmore, Jeremy M Grimshaw, Duncan J Stewart, Kavita Singh, Lauralyn McIntyre, Canadian Critical Care Translational Biology Group
Publication date
2014/12
Source
Systematic reviews
Volume
3
Pages
1-8
Publisher
BioMed Central
Description
Background
Acute respiratory distress syndrome (ARDS) in humans is caused by an unchecked proinflammatory response that results in diffuse and severe lung injury, and it is associated with a mortality rate of 35 to 45%. Mesenchymal stromal cells (MSCs; ‘adult stem cells’) could represent a promising new therapy for this syndrome, since preclinical evidence suggests that MSCs may ameliorate lung injury. Prior to a human clinical trial, our aim is to conduct a systematic review to compare the efficacy and safety of MSC therapy versus controls in preclinical models of acute lung injury that mimic some aspects of the human ARDS.
Methods/Design
We will include comparative preclinical studies (randomized and non-randomized) of acute lung injury in which MSCs were administered and outcomes compared to animals given a vehicle control. The primary …
Scholar articles
MM Lalu, D Moher, J Marshall, D Fergusson, SHJ Mei… - Systematic reviews, 2014